FDA proposes comparative approval standards for new opioids

FDA is moving to establish comparative effectiveness standards for approval of new opioids, according to draft guidance issued Thursday on conducting benefit-risk assessments.

Former FDA Commissioner Scott Gottlieb proposed such a standard shortly before he left the position.

Read the full 371 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE